60-second summary
If you only remember five things, remember these:
- This walkthrough describes, step by step, what taking part in an HS trial can involve.
- It covers finding a study, screening, consent, visits, diaries, and finishing or withdrawing.
- Screening can end in not being eligible. That is common and says nothing about you.
- Trials add appointments, travel and paperwork to a life that already includes HS care.
- It describes a general process — every study has its own protocol and requirements.
Knowing the shape of the process makes it easier to judge whether a specific trial would fit your life before you commit to anything.
Details differ between studies and countries. Nothing here predicts whether you would be eligible for, or benefit from, a particular trial.
If a study interests you, note your questions about time, travel and follow-up before contacting the study centre.
This summary is written and updated together with the full text. The evidence, limitations and sources stay unchanged in the article below.
Continue to the detailed explanationDeciding whether to look into a clinical trial is a personal choice, and it helps to know what the experience can actually look like. This guide walks through a typical participant journey for a hidradenitis suppurativa (HS) study, in roughly the order things happen. Studies differ, so treat this as a map, not a rulebook. Depending on the study, participants may be asked to do some, but not all, of what is described here. Reading it commits you to nothing.
1–2. Finding a study and reading the basic information
Most journeys start with a search — through a doctor, a patient group, or a tool like our Trial Finder. A search result gives you the basics: the condition, the study’s status, where it is running, and a link to the public registry entry. Remember that appearing in a search does not mean you are eligible; it means the study is worth asking about.
3–4. Contacting the study centre and first contact
If a study interests you, the next step is usually to contact the study centre by phone or email, often using the contact details in the registry entry. This first conversation is low-stakes: you can describe your situation in general terms, ask what the study involves, and decide whether to go further. You are not committing to anything by asking.
5–6. Participant information and the informed-consent discussion
If you and the team both want to continue, you will receive a participant information sheet — a plain-language document describing the purpose, what you would do, the possible risks and benefits, and your rights. This leads to the informed-consent discussion, where the team explains the study and answers your questions, and you decide freely whether to sign. Consent is not a trap door: you can ask questions at any time afterwards and withdraw later. Bringing our questions checklist can make this conversation easier.
7–8. Screening, and learning you may not be eligible
Before enrolment there is usually a screening visit. The team checks the detailed inclusion and exclusion criteria — reviewing your history and often running tests such as blood work or a skin assessment. It is completely normal to be screened and then told you do not meet the criteria. That can be disappointing, but it is not a judgement about you; it is how studies protect participants and keep their results meaningful. Your usual care continues either way.
9–11. Baseline visits, randomisation and receiving a treatment
If you enrol, a baseline visit records your starting point — for example, counting lesions or completing questionnaires. In many trials you are then assigned to a group by randomisation (a computer, not a person, decides), and you may receive the investigational treatment, a comparison treatment or a placeboPlacebo: An inactive substance, usually identical in appearance to the real drug, used in clinical trials to control for the meaningful placebo response in Acne Inversa.. In “blinded” studies you may not know which you receive, because expectations can influence how symptoms are judged. It is normal to feel uncertain about this; the team can explain the odds and the safety rules that let them find out quickly if a medical need arises.
12–15. Clinic visits, procedures, diaries and reporting side effects
Participation usually means visits on a schedule. Depending on the study, participants may be asked to have physical examinations, blood tests, or photographs of affected areas, and to keep a symptom diary or complete questionnaires rating pain, drainage or quality of life. You will also be asked to report side effects — anything you notice — so the team can track safety. None of these measurements are there to catch you out; they are how the study learns whether the treatment helps.
Medical photography of sensitive body areas can feel uncomfortable, and discussing intimate regions is a real barrier for many people with HS. You can ask who will see the images, how they are stored, whether a chaperone can be present, and whether particular staff can carry out sensitive parts of an exam. A good team expects these questions.
16–17. Time commitment, travel and everyday life
Being realistic about logistics matters as much as the medical detail. Ask how many visits there are and how long each takes, because the total can add up. Consider travel distance, parking, time away from work, and childcare. Depending on the study, travel or other expenses may be reimbursed — ask directly what is covered, as this varies a lot between studies. If the practical burden does not fit your life right now, that is a valid reason not to take part.
18–20. Your normal doctor, changing circumstances and withdrawing
Taking part does not replace your usual care. Ask how the study team will communicate with your normal treating doctor, and who to contact if your symptoms worsen. Life changes — a new job, a pregnancy, a move, a flareFlare: A period of acute worsening in a chronic condition. In Acne Inversa, a flare may be triggered by stress, hormonal changes, friction, or other factors and can manifest as new nodules, abscesses, or increased pain. — and you can discuss how these affect participation. Above all, remember that you can withdraw at any time, for any reason, without giving a justification and without it affecting your normal medical care. Telling the team lets them arrange any final safety checks.
21–23. Completing the trial, results and what comes after
If you complete the study, there may be a final visit and follow-up assessments. Afterwards the data is analysed. Increasingly, summaries of results are shared with participants and posted in public registries such as ClinicalTrials.gov or the EU Clinical Trials Information System — ask the team how and when you will be told. What happens next varies: continued access to an investigational treatment is not guaranteed and depends on the study and later regulatory decisions. Your own doctor can help you plan your ongoing care regardless of the outcome.
The emotional side is real
Beyond logistics, there is an emotional dimension: hope, uncertainty about which treatment you received, worry about a placebo, concerns about privacy, and the general weight of living with a chronic condition. These feelings are normal and worth naming with the study team or people you trust. Deciding not to take part is an equally valid outcome.
A note on personal stories
Imagine someone we’ll call a composite participant. They find a recruiting study near their city, phone the centre, and feel reassured by an unhurried first conversation. At screening they learn the criteria in detail; they are eligible, and they take a week to decide. During the study they attend regular visits, keep a short pain diary, and feel uneasy about the photographs at first — until the team explains exactly who will see them. Midway through, work gets busy and they consider stopping; the team offers to adjust the visit timing, and they continue. Whatever the result, they say the clearest benefit was feeling closely monitored and heard. This is not a promise of how any real study will go — it is a picture assembled from what participants and research organisations commonly describe.
Before you contact a centre
If you want the concepts first, read what a clinical trial is. For the bigger picture of how research shaped today’s treatments, see how clinical trials changed HS treatment. When you are ready, search for open HS studies, take the questions checklist with you, and return to the clinical trials hub any time. For a dermatologyDermatology: The medical specialty concerned with diagnosing and treating skin conditions. Acne Inversa is often managed by dermatologists, although surgery and other specialties may also be involved. appointment, our 15 questions for your dermatologist may also help.
Terms explained in this article
Quick definitions of the key medical terms. Select any term for its full glossary entry.
- Placebo
- An inactive substance, usually identical in appearance to the real drug, used in clinical trials to control for the meaningful placebo response in Acne Inversa.
- Flare
- A period of acute worsening in a chronic condition. In Acne Inversa, a flare may be triggered by stress, hormonal changes, friction, or other factors and can manifest as new nodules, abscesses, or increased pain.
- Dermatology
- The medical specialty concerned with diagnosing and treating skin conditions. Acne Inversa is often managed by dermatologists, although surgery and other specialties may also be involved.
FAQ
What happens at the screening visit?
The study team reviews your medical history, explains the study, and may run tests such as blood work or a skin examination to check the detailed inclusion and exclusion criteria. Screening is also your chance to ask questions. It is common to be screened and then learn you are not eligible.
What if I am not eligible?
Not being eligible is not a personal judgement — the criteria exist to keep participants safe and to make results reliable. Your normal medical care continues unchanged, and your own doctor can discuss other options, including different studies.
Will I definitely receive the new treatment?
Not necessarily. Depending on the study you may be assigned to the investigational treatment, a comparison treatment or a placebo, usually at random. The team will explain how assignment works and how likely each option is before you consent.
Can I leave the study once I have started?
Yes. You can withdraw at any time, for any reason, without giving a justification and without affecting your normal care. Telling the team allows any final safety checks to be arranged.
Are my travel costs and time covered?
This varies by study. Some reimburse travel or other expenses; some do not. Ask the study team directly what is covered before you enrol so there are no surprises.
References
- Learn About Clinical Studies (participant information) ClinicalTrials.gov, U.S. National Library of Medicine
- Clinical Trials: What Patients Need to Know U.S. Food and Drug Administration
- Informed consent and participant rights in clinical research EUPATI (European Patients' Academy on Therapeutic Innovation)
- Understanding clinical research participation CISCRP (Center for Information and Study on Clinical Research Participation)